Advanced search×

The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels.

R R Krysiak, W W Zmuda, and B B Okopien

J Intern Med 271(1):32-42 (2012) PMID 21623963

Studies assessing the extra-lipid effects of ezetimibe have provided contrasting results. In the present study, we compared the effects of ezetimibe and simvastatin, administered alone or in combination, on the secretory function of human lymphocytes, systemic inflammation and endothelial function in subjects with elevated cholesterol levels.

DOI: 10.1111/j.1365-2796.2011.02394.x
Version: za2963e q8za9 q8zb3 q8zc1 q8zdd q8zee q8zf0 q8zg1

Similar articles you may find interesting…

  1. Pathological investigation of oxidative stress in the post-genomic era.
    Shinya S Toyokuni and Shinya S Akatsuka

    Pathol Int 57(8):461-73 (2007) PMID 17610470

    Aerobes, including humans, are consistently exposed to oxidative stress by consuming oxygen. The biological significance of oxidative stress via reactive oxygen and nitrogen species consists of two stages: reversible redox regulation and irreversible oxidative molecular damage, which are sometimes i...
  2. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.
    Dipak D Panigrahy, Arja A Kaipainen, ... Mark W MW Kieran

    Proc Natl Acad Sci U S A 105(3):985-90 (2008) PMID 18199835 PMCID 2242705

    We have demonstrated recently that peroxisome proliferator-activated receptor (PPAR)alpha deficiency in the host leads to overt inflammation that suppresses angiogenesis via excess production of thrombospondin (TSP)-1 and prevents tumor growth. Hence, we speculated that pharmacologic activation of P...
  3. Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma
    Gary R Hudes, Anna Berkenblit, ... Janice Dutcher

    Semin Oncol (2009) PMID 19963097

    Clinical trials have validated the importance of mammalian target of rapamycin (mTOR) as a therapeutic target in patients with advanced renal cell carcinoma (RCC). The TORC1 complex controls translation of key proteins involved in cell proliferation and regulates the expression and stability of hypo...